Sugi Predict

Sugi Predict / Targets / KAT2B

KAT2B

Histone acetyltransferase KAT2B · Q92831 · KAT2B on Sugi Atlas →

47,476 patent compounds predicted against KAT2B, 27,521 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL22657 SCHEMBL22657 1.00 12/20
SCHEMBL81082 SCHEMBL81082 0.59 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL155941) 0.50 11/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL158635) 0.50 11/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL156132) 0.42 9/20
SCHEMBL80967 SCHEMBL80967 0.58 8/20
SCHEMBL112790 SCHEMBL112790 0.49 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL141377) 0.61 6/20
SCHEMBL79450 SCHEMBL79450 0.50 6/20
SCHEMBL111343 SCHEMBL111343 0.49 6/20
SCHEMBL111539 SCHEMBL111539 0.59 5/20
SCHEMBL111519 SCHEMBL111519 0.52 4/20
SCHEMBL303646 SCHEMBL303646 0.47 4/20
SCHEMBL198602 SCHEMBL198602 0.47 4/20
SCHEMBL111935 SCHEMBL111935 0.42 4/20
SCHEMBL14390 SCHEMBL14390 0.40 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL295131) 0.95 3/20
SCHEMBL24076 SCHEMBL24076 0.69 3/20
SCHEMBL29638 SCHEMBL29638 0.68 3/20
SCHEMBL204793 SCHEMBL204793 0.61 3/20

Clinical trials — most relevant to KAT2B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Vorinostat in Children PHASE1/PHASE2COMPLETED
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid EARLY_PHASE1COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Investigation of the Genetic and Environmental Causes of Autism: a Multi-Center Study nanNOT_YET_RECRUITING
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
DNA Methylation and Autoimmune Thyroid Diseases nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KAT2B binder may also engage these)

ProteinNameSimilarity
Q9JHD1 — 1.000 Q9JHD1 →
Q9JHD2 — 1.000 Q9JHD2 →
Q1LUC3 — 1.000 Q1LUC3 →
KAT2A Histone acetyltransferase KAT2A 1.000 landscape →
A0A0R4IXF6 — 1.000 A0A0R4IXF6 →
O54828 — 0.993 O54828 →
Q5RHD1 — 0.993 Q5RHD1 →
Q5JCS6 — 0.991 Q5JCS6 →
Q9QY01 — 0.991 Q9QY01 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.991 landscape →
Q6DN90 — 0.991 Q6DN90 →
Q6EE22 — 0.990 Q6EE22 →
A6H8H5 — 0.990 A6H8H5 →
O14607 — 0.990 O14607 →
Q07E15 — 0.990 Q07E15 →
Q02225 — 0.990 Q02225 →
Q9Z136 — 0.990 Q9Z136 →
Q08AX9 — 0.990 Q08AX9 →
ULK2 Serine/threonine-protein kinase ULK2 0.990 landscape →
Q92833 — 0.990 Q92833 →
E9PUQ8 — 0.990 E9PUQ8 →
Q80U16 — 0.990 Q80U16 →
Q62925 — 0.989 Q62925 →
Q62315 — 0.989 Q62315 →
Q9TU15 — 0.989 Q9TU15 →
Q9H2G9 — 0.989 Q9H2G9 →
Q8R0S2 — 0.989 Q8R0S2 →
Q09YI1 — 0.989 Q09YI1 →
RORC Nuclear receptor ROR-gamma 0.989 landscape →
Q68FF0 — 0.989 Q68FF0 →